Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR6 | O00574 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL3218339 | 0.94 | CXCR6 (0.42) | CXCR6CHEK1HTR2BSMN1; SMN2GID4 | |
| SCHEMBL13490684 | 0.87 | EPHX2 (0.50) | CXCR6CHEK1HTR2BSMN1; SMN2USP30 | |
| SCHEMBL13490663 | 0.86 | SMN1; SMN2 (0.47) | CXCR6CHEK1HTR2BSMN1; SMN2GID4 | |
| SCHEMBL13490682 | 0.86 | RAB9A (0.62) | CXCR6CHEK1RAB9A | |
| SCHEMBL13490394 | 0.86 | NPC1 (0.45) | CXCR6CHEK1HTR2BSMN1; SMN2SMYD3 | |
| SCHEMBL13490710 | 0.85 | CHRM4 (0.47) | CXCR6CHEK1HTR2BSMN1; SMN2RAB9A | |
| SCHEMBL14192843 | 0.85 | CHRM4 (0.47) | CXCR6CHEK1HTR2BSMN1; SMN2RAB9A | |
| SCHEMBL14192836 | 0.85 | CHEK1 (0.46) | CXCR6CHEK1HTR2BSMN1; SMN2USP30 | |
| Hydrochloric Acid SCHEMBL3215198 | 0.85 | NPC1 (0.44) | CXCR6CHEK1HTR2BSMN1; SMN2SMYD3 | |
| SCHEMBL13490701 | 0.85 | HTR2B (0.46) | CXCR6CHEK1HTR2BSMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029615-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2010-02-04 | — | — | US | disclosed |
| US-20100029615-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER INC. | 2010-02-04 | — | — | US | disclosed |
| WO-2008075196-A1 | BENZIMIDAZOLE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029615-A1 | BENZIMIDAZOLE DERIVATIVES | ACIN1, HAT1, CCNE1 | CXCR6 3847/4885CHEK1 1651/4885HTR2B 3456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.